Abnormal Glucose Tolerance
Conditions
Brief summary
Evaluation of the safety and effects on glycemic control of medical food formulation WBF-0031 in subjects with abnormal glucose control.
Detailed description
The current study aims to investigate if altering the microbiome though Pendulum Glucose Control supplementation can have implications aimed at maintaining normal blood glucose levels that are critical for preventing diabetes and its metabolic complications. The experimental design consists of two-12 week treatment periods in subjects with prediabetes, as defined by the National Diabetes Prevention Program (DPP) criteria. The first study period of 12 weeks will be double-blinded, placebo-controlled. The Pendulum Glucose control and placebo will be in a capsule form and identical in appearance, and dispensed to each participant according to the randomization schedule in the first 12 weeks. All subjects will receive the active product (Pendulum Glucose Control) in the second, subsequent 12 week period. Fasting total cholesterol, triglycerides, LDL, and HDL cholesterol, Fasting insulin and Glucose, High sensitivity C Reactive Protein (hsCRP), Chemistry 14, and HbA1c will be obtained at baseline, and during first and second study period, as well as vital signs of weight, BP, and waist circumference. In addition, CGM (Abbott System Freestyle Libre Pro) data collection will be done three times during the study as noted in Schedule of Events. Baseline Blinded CGM will be performed for approximately 14 days prior to starting the intervention with Pendulum Glucose Control. Second Blinded CGM period for approximately 14 days will occur mid-way through the intervention (weeks 5 and 6) and a third period of Blinded CGM wear will occur during the last 2 weeks of the intervention (weeks 11 and 12). During the Baseline, study period one and period 2 a mixed meal tolerance consisting of 2 Boost Shakes will be given on day 5 of each sensor wear. At the completion of the study, analysis of the vital signs, laboratory values, CGM data for average glucose, standard deviation, TIR (time in range), as well as glycemic results of MMT for each time interval; baseline, study period one, and two.
Interventions
DIETARY_SUPPLEMENTWBF-0031
Medical food formulation WBF-0031
Sponsors
Pendulum Therapeutics
Eden Miller
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Study product was provided for each arm in identical capsules.
Intervention model description
Balanced randomization first arm, formulation WBF-0031 and placebo. Second arm all subjects formulation WBF-0031.
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Between 18-80 years of age 2. BMI \< 45 kg/m2 3. Eligible based on a recent (within the past year) blood test meeting one of these specifications: 1. Fasting glucose of 100 to 125 mg/dl 2. Plasma glucose measured 2 hours after a 75-gram glucose load of 140 to 199 mg/dl 3. A1c of 5.7 to 6.4% 4. Clinically diagnosed gestational diabetes mellitus (GDM) during a previous pregnancy (may be self-reported) 4. Willing to comply with study requirements 5. Provide written informed consent
Exclusion criteria
1. Known diagnosis of diabetes / taking any medication for the treatment of diabetes including the off-label use of a GLP-1 receptor agonist, SGLT-2, or metformin) within the last 3 months for weight loss. 2. Active participation in another lifestyle or behavior change education or research program (DPP or weight loss program) 3. Current treatment with systemic corticosteroids (topical and nasal steroids are allowed) 4. Subjects who have received an antibiotic, antifungal, antiparasitic, or antiviral treatment within 30 days prior to study entry 5. Pregnant women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time spent in target blood glucose | Three 14 day intervals | Difference in daily glucose levels as measured by the amount of time spent in target blood glucose for each CGM wear period. Adjustable glucose thresholds will be set as follows:\<60 mg/dL, \<70 mg/dL, \>140 mg/dL, \>180 mg/dL and \>240 mg/dL. The percent of values above, below, and between these points will be calculated. |
| Safety Assessment of Adverse Events | 30 weeks | Safety assessed via spontaneous adverse events reported during the study period and changes in chemistry 14 panel |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incremental Glucose Area Under the Curve (AUC) from baseline | 24 weeks | Twelve and 24 week difference from baseline in incremental Glucose AUC during a standard Meal Tolerance Test (MMT) |
| A1c | Week 0, Week 12, Week 24 | Improvement in A1c measured as a change in A1c levels from baseline at 12 and 24 weeks. Subjects enrolled in the study will have fasting A1c measurements at the time of enrollment and weeks, 0, 12 and 24 weeks. |
| Glucose peaks | 30 weeks | Mean and standard deviation of post-prandial peak glucose and time to peak for each meal |
| Total Glucose Area Under the Curve (AUC) from baseline | 24 weeks | Twelve and 24 week difference from baseline in total Glucose AUC during a standard Meal Tolerance Test (MMT) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Questionnaire | Week 0, Week 12, Week 24 | Quality of life questionnaire responses measured at 0, 12 and 24 weeks. |
Countries
United States
Outcome results
None listed